|
Earnings Roundup
(BioWorld Today Via Acquire Media NewsEdge) , of South San Francisco, reported a net loss of $21.9 million, or 54 cents per share, for the second quarter. As of June 30, the firm, which in June launched Zingo, a fast-acting, needle-free, local anesthetic indicated for pediatric patients, had $48.7 million in cash, cash equivalents and investments.
? DUSA Pharmaceuticals Inc., of Wilmington, Mass., reported total product revenues of $8.1 million for the second quarter, driven by a 39 percent increase in sales of dermatology product Kerastick. DUSA's net loss was $100,000, or 1 cent per share. It ended the quarter with cash, equivalents and U.S. government securities of $22.7 million. Shares of DUSA (NASDAQ:DUSA) gained 24 cents, or 16.7 percent, to close Friday at $1.68.
? Halozyme Therapeutics Inc., of San Diego, posted a net loss of $11 million, or 14 cents per share, for the second quarter. The firm reported sales of Cumulase, recombinant human hyaluronidase for cumulus removal in the IVF process, of $48,000.
? ISTA Pharmaceuticals Inc., of Irvine, Calif., reported total net revenue of $17.8 million for the second quarter, with most of that coming from sales of Xibrom, its ocular nonsteroidal anti-inflammatory drug, which brought in $13.6 million. The company posted a net loss of $8.5 million, or 26 cents per share, and ended the three-month period with $21.8 million in cash, equivalents and short-term investments. ISTA's stock (NASDAQ:ISTA) jumped 50 cents, or 36 percent, Friday to close at $1.89.
? Jazz Pharmaceuticals Inc., of Palo Alto, Calif., reported second-quarter revenues of $15.5 million. Sales of Xyrem (sodium oxybate oral solution) increased 29 percent to $12.4 million, compared with $9.6 million for the second quarter of 2007. The quarter also included the first net sales of Luvox (fluvoxamine maleate) extended release, a selective-serotonin-reuptake inhibitor, which was launched in April, at $700,000. At the end of the quarter, Jazz reported $54.7 million in cash, cash equivalents and marketable securities.
? Labopharm Inc., of Laval, Quebec, reported second-quarter sales of once-daily tramadol totaling $3.9 million, down from the $4.1 million reported in the second quarter of 2007. Overall revenue for the three-month period was $4.9 million. The company reported a net loss of $10.1 million, or 18 cents per share. As of June 30, it had cash, equivalents and marketable securities of $55.3 million. Shares of Labopharm (NASDAQ:DDSS) closed at $1.25 Friday, down 8 cents.
?
?
Copyright ? 2008 Thomson BioWorld, All Rights Reserved.
[ Back To cable.tmcnet.com's Homepage ]
|